+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Angina Pectoris Drugs Market by Type (Prinzmetal Angina, Stable Angina, Unstable Angina), Drugs (Anti-Ischemic Agents, Antihypertensive Agents, Antiplatelet Agents), Route of Administration, Distribution Channel, End-Users - Forecast 2024-2030

  • PDF Icon

    Report

  • 196 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5715602
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Angina Pectoris Drugs Market size was estimated at USD 1.14 billion in 2023, USD 1.20 billion in 2024, and is expected to grow at a CAGR of 5.39% to reach USD 1.65 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Angina Pectoris Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Angina Pectoris Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Angina Pectoris Drugs Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Limited, Alkem Laboratories Ltd., Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Centurion Remedies Private Limited, Dr. Reddy's Laboratories, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline PLC, Intas Pharmaceuticals Ltd., Ipca Laboratories Ltd., Lupin Ltd., Macleods Pharmaceuticals Pvt Ltd., Mankind Pharma, Merck & Co. Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi-Aventis Groupe S.A., Sumitomo Corporation, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Torrent Pharmaceuticals Ltd.

Market Segmentation & Coverage

This research report categorizes the Angina Pectoris Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Prinzmetal Angina
    • Stable Angina
    • Unstable Angina
  • Drugs
    • Anti-Ischemic Agents
    • Antihypertensive Agents
    • Antiplatelet Agents
    • Beta-Adrenergic Blocking Agents
    • Calcium Channel Blockers
    • Nitrates
    • Statins
  • Route of Administration
    • Oral
    • Parenteral
    • Transdermal
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End-Users
    • Homecare
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Angina Pectoris Drugs Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Angina Pectoris Drugs Market?
  3. What are the technology trends and regulatory frameworks in the Angina Pectoris Drugs Market?
  4. What is the market share of the leading vendors in the Angina Pectoris Drugs Market?
  5. Which modes and strategic moves are suitable for entering the Angina Pectoris Drugs Market?

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Angina Pectoris Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing burden of lifestyle diseases couple with rise in cases of heart related disorders
5.1.1.2. Augmentation of novel drug delivery systems
5.1.1.3. Government suppport in strengthening the prevention and control of cardiovascular disease
5.1.2. Restraints
5.1.2.1. Concerns regarding side effects associated with certain drug classes
5.1.3. Opportunities
5.1.3.1. Technological advancements towards personalized cardiovascular medicine
5.1.3.2. Proliferation in the number of drug approvals and clinical research
5.1.4. Challenges
5.1.4.1. Dearth of skilled and experienced professionals
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Angina Pectoris Drugs Market, by Type
6.1. Introduction
6.2. Prinzmetal Angina
6.3. Stable Angina
6.4. Unstable Angina
7. Angina Pectoris Drugs Market, by Drugs
7.1. Introduction
7.2. Anti-Ischemic Agents
7.3. Antihypertensive Agents
7.4. Antiplatelet Agents
7.5. Beta-Adrenergic Blocking Agents
7.6. Calcium Channel Blockers
7.7. Nitrates
7.8. Statins
8. Angina Pectoris Drugs Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
8.4. Transdermal
9. Angina Pectoris Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Angina Pectoris Drugs Market, by End-Users
10.1. Introduction
10.2. Homecare
10.3. Hospitals
10.4. Specialty Clinics
11. Americas Angina Pectoris Drugs Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Angina Pectoris Drugs Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Angina Pectoris Drugs Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. Alembic Pharmaceuticals Limited
15.1.2. Alkem Laboratories Ltd.
15.1.3. Astellas Pharma Inc.
15.1.4. AstraZeneca PLC
15.1.5. Bausch Health Companies Inc.
15.1.6. Bayer AG
15.1.7. Centurion Remedies Private Limited
15.1.8. Dr. Reddy's Laboratories
15.1.9. Eli Lilly and Company
15.1.10. Gilead Sciences, Inc.
15.1.11. GlaxoSmithKline PLC
15.1.12. Intas Pharmaceuticals Ltd.
15.1.13. Ipca Laboratories Ltd.
15.1.14. Lupin Ltd.
15.1.15. Macleods Pharmaceuticals Pvt Ltd.
15.1.16. Mankind Pharma
15.1.17. Merck & Co. Inc.
15.1.18. Novartis AG
15.1.19. Otsuka Pharmaceutical Co., Ltd.
15.1.20. Pfizer Inc.
15.1.21. Sanofi-Aventis Groupe S.A.
15.1.22. Sumitomo Corporation
15.1.23. Sun Pharmaceutical Industries Ltd.
15.1.24. Teva Pharmaceutical Industries Ltd.
15.1.25. Torrent Pharmaceuticals Ltd.
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
List of Figures
FIGURE 1. ANGINA PECTORIS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ANGINA PECTORIS DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. ANGINA PECTORIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ANGINA PECTORIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ANGINA PECTORIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ANGINA PECTORIS DRUGS MARKET DYNAMICS
FIGURE 7. ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
FIGURE 10. ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 14. ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 16. ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. ANGINA PECTORIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 26. ANGINA PECTORIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Alembic Pharmaceuticals Limited
  • Alkem Laboratories Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Centurion Remedies Private Limited
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Intas Pharmaceuticals Ltd.
  • Ipca Laboratories Ltd.
  • Lupin Ltd.
  • Macleods Pharmaceuticals Pvt Ltd.
  • Mankind Pharma
  • Merck & Co. Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi-Aventis Groupe S.A.
  • Sumitomo Corporation
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.

Methodology

Loading
LOADING...

Table Information